AWS
TEVA icon

Atria Wealth Solutions’s Teva Pharmaceuticals TEVA Stock Holding History

Atria Wealth Solutions’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-17,933
Closed -$137K – 1854
2022
Q2 		$137K Buy
+17,933
New +$156K ﹤0.01% 1504

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Atria Wealth Solutions's TEVA Position: Q3 2024 in Review

Atria Wealth Solutions sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 16,796 shares — an estimated $273K sold.

Atria Wealth Solutions first reported a position in TEVA in Q1 2022 and held it in 9 quarters. The position peaked at $285K in Q1 2022. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • Atria Wealth Solutions reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Atria Wealth Solutions sold 16,796 Teva Pharmaceuticals shares in Q3 2024, an estimated $273K.
  • Atria Wealth Solutions first reported a position in Teva Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Atria Wealth Solutions's Teva Pharmaceuticals position peaked at $285K in Q1 2022.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on Atria Wealth Solutions's 13F filing for Q3 2024, filed 8 Nov 2024.